The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 04, 2014
Filed:
Oct. 07, 2010
Andras Mravik, Budapest, HU;
Imre Koehegyi, Budapest, HU;
Laszlo Pongo, Kerepes, HU;
Balazs Volk, Budapest, HU;
Gabor Nemeth, Budapest, HU;
Jozsef Barkoczy, Budapest, HU;
Kalman Nagy, Budapest, HU;
Gyoergy Ruzsics, Budapest, HU;
Judit Broda, Budapest, HU;
Andras Dancso, Budapest, HU;
Adrienn Keszthelyi, Budapest, HU;
Jozsef Debreczeni, Budapest, HU;
Andras Mravik, Budapest, HU;
Imre Koehegyi, Budapest, HU;
Laszlo Pongo, Kerepes, HU;
Balazs Volk, Budapest, HU;
Gabor Nemeth, Budapest, HU;
Jozsef Barkoczy, Budapest, HU;
Kalman Nagy, Budapest, HU;
Gyoergy Ruzsics, Budapest, HU;
Judit Broda, Budapest, HU;
Andras Dancso, Budapest, HU;
Adrienn Keszthelyi, Budapest, HU;
Jozsef Debreczeni, Budapest, HU;
Egis Gyogyszergynar Nyilvanosan Muekoedoe Reszvenytarsasag, Budapest, HU;
Abstract
The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.